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S U M M A R Y
Objective: To measure the expression levels of sputum and serum microRNA-144 (miR-144) before and
after the treatment of patients with tuberculosis (TB).
Methods: Details of the cases of a total of 124 TB patients were collected at Qilu Hospital of Shandong
University between April 2014 and April 2015. Fifty-three of these patients had sputum positive for
bacteria and a cavity on imaging (group A), 20 patients had sputum negative for bacteria and a cavity on
imaging (group B), and 51 patients had sputum negative for bacteria and no cavity on imaging (group C).
One hundred seventeen healthy people who attended the hospital for a physical examination were
recruited as controls. Quantitative real-time PCR (qRT-PCR) was used to measure the levels of sputum
and serum miR-144 before anti-TB treatment and at 1 month after treatment.
Results: Before treatment, sputum and serum miR-144 expression levels in the TB patients were both
higher than those of the controls (both p < 0.05). After treatment, sputum and serum miR-144 levels in
the TB patients were signiﬁcantly lower than those measured before treatment (both p < 0.05). The
levels of sputum and serum miR-144 in the improved TB patients decreased signiﬁcantly after treatment
compared to those measured before treatment (both p < 0.001). Signiﬁcant differences were found in
sputum and serum miR-144 levels in the TB patients, with or without improvement, compared with the
healthy controls (all p < 0.05).
Conclusion: Sputum and serum miR-144 levels were signiﬁcantly upregulated in the TB patients, but
were found to decrease signiﬁcantly after anti-TB treatment.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Tuberculosis (TB) is a chronic infectious disease caused by
Mycobacterium tuberculosis.1 As one of the most serious diseases to
threaten human health, TB can invade many organs, especially the
lungs.2 According to a global TB report published in 2013, over nine
million new TB cases are diagnosed worldwide each year, with
more than three million new cases being diagnosed each year in
China, which ranks second in the world.3 The TB epidemic in some
areas of China has increased in recent years, due to the expansion
of the ﬂoating population, the spread of drug-resistant TB, and the
dual infection of TB and HIV.4 The conventional methods of TB
detection at present are sputum smears for acid-fast bacilli (AFB)* Corresponding author. Tel.: +86-18953109816.
E-mail address: quyiqing1112@163.com (Y.-Q. Qu).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).and culture; however the sensitivity of the AFB smear staining
method is low and the conventional reporting time for culture of M.
tuberculosis, the gold standard for the diagnosis of M. tuberculosis, is
as long as 2 months. This delay makes it difﬁcult to meet clinical
needs.5 Therefore, it is particularly important to identify a new TB
clinical index with high sensitivity and speciﬁcity.
MicroRNAs (miRNAs) are highly conserved non-coding RNA
fragments with abundant expression in cells.6 miRNAs are
generally 18–25 nt in length and can inhibit the expression of
genes through combining the 30-translated region of target gene
mRNAs.6 miRNAs are involved in many important processes,
including early embryonic development, cell proliferation, cell
apoptosis, and cell death.7 Recent studies have shown that serum
miRNAs may represent candidate biological markers for the early
diagnosis of diseases, including cancer of the stomach, colon
cancer, and others.8,9 Despite their short length, miRNAs affect the
expression of a variety of proteins and have shown excellent
properties as biomarkers in many diseases.10–12 Some studies haveciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Y. Lv et al. / International Journal of Infectious Diseases 43 (2016) 68–73 69identiﬁed a group of miRNAs that are expressed speciﬁcally and
play regulatory roles in the interaction between M. tuberculosis and
host cells; these include miR-223, miR-144, and miR-421.13,14
Taking into consideration all of the above factors, the present study
was conducted to investigate the application of miR-144 in the
diagnosis of TB. The expression levels of sputum and serum miR-
144 were measured and compared between TB patients and
healthy controls, as well as before and after anti-TB treatment.
2. Materials and methods
2.1. Participants
Details of the cases of a total of 124 TB patients (70 male and
54 female) were collected at Qilu Hospital of Shandong University
between April 2014 and April 2015. The subjects ranged in age from
12 to 59 years (mean age 27.25  8.99 years). Fifty-three of these
patients had sputum positive for bacteria and a cavity on imaging
(group A), 20 patients had sputum negative for bacteria and a cavity on
imaging (group B), and 51 patients had sputum negative for bacteria
and no cavity on imaging (group C). All of these patients were diagnosed
with TB on the basis of the typical TB clinical symptoms, bacterial
culture, and imaging examinations, and in accordance with the Health
criteria in People’s Republic of China: The legal diagnostic criteria of
infectious diseases (WS288-2008) and the revised international deﬁni-
tions in TB control of the World Health Organization (WHO).15
Patients with a conﬁrmed diagnosis, with positive sputum
examination results (smear or culture), were included directly.
Patients suspected of having TB who had negative sputum results
were examined by chest X-ray and chest computed tomography (CT),
and those whose results showed lung tissue with typical active TB
lesions were formally enrolled. All of the TB patients included were
presenting for initial treatment and met at least one of the following
conditions: (1) the patient had never been treated previously for TB
with anti-TB drug treatment; (2) the patient was receiving the
standard chemotherapy scheme, but had not completed the course of
treatment; (3) the patient had received irregular chemotherapy for
less than 1 month. The patient was excluded if he/she had (1) used
drugs that may affect immune functions within the previous
3 months, such as immunosuppressive drugs or immunopotentiator;
(2) a serious heart, liver, kidney, or spleen disease; (3) silicosis, a
tumor, psychosis, epilepsy, an immune allergic disease, or a severe
bacterial or fungal infection of the lungs; (4) a family history of
genetic disease, similar medical symptoms of TB, HIV infection, long-
term use of hormones, an organ transplant, or any other disease
that might lead to immunocompromise. Pulmonary TB patients
were initially administered isoniazid, rifampicin, pyrazinamide,
ethambutol, and streptomycin at conventional doses for 1 month,
with liver function carefully protected.
One hundred seventeen healthy individuals (70 male and
47 female) who attended the hospital for a physical examination
during the same time period, were recruited as controls. They
ranged in age from 10 to 51 years (mean age 27.49  8.80 years).
The subjects in the control group were included only if they had
normal biochemical indices in all routine examinations and no
organic diseases. The age and sex distribution in the two groups of
patients were comparable (all p > 0.05).
This study was approved by the ethics committee of the
hospital. Informed consent was obtained from all of the patients, as
well as their families. All of the procedures in this study were
performed in compliance with the Declaration of Helsinki.16
2.2. Data collection, follow-up, and indices
Clinical data, such as sex and age, were obtained for all of the
study subjects. Laboratory data, including chest X-ray or chest CTﬁndings and sputum TB bacteria results, were collected for the TB
patients. Patients were subjected to sputum AFB smear three times
before anti-TB treatment and at 1 month after treatment, and chest
X-ray or chest CT once before treatment and at 1 month after
treatment. The observation period lasted for 1 month, during
which the TB patients received intensive treatment. The expres-
sion levels of sputum and serum miR-144 and the change in
disease state were observed before and after treatment in the TB
patients. The deﬁnitions for the change in disease state were as
follows: (1) an ‘improved state’ referred to the situation in which
the clinical symptoms had improved, with sputum examination
results for bacteria changing from positive to negative, or with
absorption on chest CT being equal to or greater than one third, or
with resolution of the pulmonary cavity or shrinking of the cavity
by at least one third; (2) a ‘non-improved state’ referred to the
situation in which the clinical symptoms showed no evident
improvements, the sputum was positive for bacteria, absorption on
chest CT was less than one third, the lesions had increased, or the
pulmonary cavity had not changed or had even become larger.17
2.3. Sample collection
Venous blood and sputum specimens of the TB patients were
collected before anti-TB treatment and at 1 month after treatment.
The same samples were collected from the control group subjects on
the day on which they took the physical examination. Samples were
stored at 4 8C for 30 min, after which the serum samples were
centrifuged at low temperature for 10 min (centrifugal radius
12.5 cm, 3000 rpm) and the supernatant was extracted, subpackaged
into 1.5 ml eppendof tubes, and stored at 80 8C for later testing.
In accordance with the methods of Pinto-Plata et al.,18 the
subjects were asked to rinse their mouth with water 10 min before
sputum induction and then to inhale 200 mg salbutamol; they
inhaled atomized 3% sodium chloride solution for 5 min . Before
obtaining deep cough sputum, the subjects were required to rinse
their mouth with hydrogen peroxide. After the removal of nasal
mucus, the patients coughed deeply to obtain sputum. The patients
coughed once every 3 min, but could not expectorate beyond
10 min. The volume of collected sputum was required to be not less
than 1 ml and without saliva.
Immediately following collection, 1 ml or 0.5 ml sputum
without saliva was placed into centrifuge tubes, diluted with
3–5 multiple phosphate buffered saline, and oscillated vigorously
for 2 to 3 min; these were then vortex oscillated for 1 to 2 min to
evenly dilute the sputum. The induced sputum samples were
centrifuged at 3500 rpm at 4 8C for 20 to 30 min and the
supernatant was extracted and stored at 70 8C for later testing.
As quality control for the sputum examination, two or three
sputum cytology smears were prepared and then air dried at room
temperature. These were subjected to Wright–Giemsa staining and
the cells in the sputum cytology smears were counted and
classiﬁed under a microscope. The specimen qualiﬁed for the study
if more than 25 white blood cells and fewer than 10 squamous
epithelial cells were present in each sputum sample, as seen under
a low-magniﬁcation microscope.20 The samples had to be checked
and treated immediately; if this was not possible, the samples
were required to be stored at 4 8C and to be tested within 24 h.
2.4. Measuring miR-144 expression levels by quantitative real-time
PCR (qRT-PCR)
Total RNAs were extracted from the sputum supernatant and
serum using the Trizol reagent (Invitrogen, USA), and the RNA
samples were further puriﬁed using the RNeasy Mini Kit (Qiagen,
USA). The quality of the extracted RNAs was inspected by gel
electrophoresis and ultraviolet spectrophotometer. The RNAs were
Y. Lv et al. / International Journal of Infectious Diseases 43 (2016) 68–7370catalyzed and synthesized into cDNA using the PrimerScript RT
reagent kit (Takara Bio, Inc., Dalian, China). The reverse transcription
(RT) primer sequence for miR-144 was 50-GTCGTATCCAGTGCGTG-
TCGTGGAGTCGGCAATTGCACTGGATACGACAGTACAT-30; the RT
primer sequence of internal reference U6 was 50-CGCTTCAC-
GAATTTGCGTGTCAT-30. RNA ampliﬁcation was conducted using
the SYBR Premix ExTaq qRT-PCR reagent kit (Takara-Bio, Shiga,
Japan). The PCR primer sequences of miR-144 were 50-ATC-
CAGTGCGTGTCGTG-30 (sense) and 50-TGCTTATACAGTATAGATG-30
(antisense); the PCR primer sequences of internal reference U6 were
50-GCTTCGGCAGCACATATACTAAAAT-30 (sense) and 50-CGCTTCAC-
GAATTTGCGTGTCAT-30 (antisense). The PCR protocol was as
follows: denaturing at 95 8C for 5 min; 40 cycles of 95 8C for 10 s,
60 8C for 20 s, and 72 8C for 20 s; ﬁnally 78 8C for 20 s (collecting
ﬂuorescence). The speciﬁcity of the PCR reaction was assessed
by product melting curve and 3.5% NuSieve agarose gel electropho-
resis. Opticon Monitor 3 software (BioRad) was employed to analyze
the PCR results. The threshold was set manually at the lowest
point of the parallel rise of the logarithmic ampliﬁcation curve to
obtain a cycle threshold (Ct) value for each reaction tube. Data were
analyzed by adopting the 2DDCt method. The relative expression of
a targeted gene was calculated using the formula 2DDCt; the folds
(2DDCt) showed the multiple proportions of the targeted gene
expression in the experimental and control groups, and
DDCt = (Cttarget gene  Ctreference gene)the experimental group  (Cttarget
gene  Ctreference gene)the control group.
2.5. Statistical methods
The data were analyzed using IBM SPSS Statistics version
19.0 software (IBM Corp., Armonk, NY, USA). Quantitative data
were recorded as the mean  standard deviation (mean  SD).
Comparisons of sputum and serum miR-144 levels obtained before
and 1 month after anti-TB treatment were conducted by paired-
samples t-test. The other group comparisons were conducted by use
of the independent-samples t-test. The I2 test was applied to compare
the count data among groups. Receiver operating characteristic (ROC)
curves were used to evaluate the diagnostic efﬁcacy. The area under
the ROC curve (AUC) was calculated to assess the diagnostic efﬁcacy
of sputum and serum miR-144. Results were considered to be
statistically signiﬁcant when the p-value was less than 0.05.
3. Results
3.1. Expression of sputum and serum miR-144 in TB patients before
treatment
The RT-PCR results showed that the sputum and serum miR-
144 expression levels in the TB patients before treatment wereA B
Figure 1. Sputum (A) and serum (B) expression levels of miR-144 in the healthy controls
***p < 0.001 compared with the healthy control group.signiﬁcantly higher than those of the controls (sputum
1.85  0.71 vs. 1.02  0.08, t = 12.93; serum 1.31  0.30 vs.
0.72  0.08, t = 7.829; both p < 0.001) (Figure 1). The sputum and
serum miR-144 expression levels were signiﬁcantly higher in group
A, B, and C patients before treatment than those in the control group.
Both sputum and serum miR-144 levels were lower in group B and
group C patients than in group A patients; they were signiﬁcantly
lower in group C patients than in group B patients (all p < 0.05).
3.2. Diagnostic value of sputum and serum miR-144 for TB
ROC analysis of sputum miR-144 showed an AUC of 0.954 (95%
conﬁdence interval (CI) 0.925–0.983, p < 0.001). When the cut-off
value was 1.185, both the sensitivity (86.29%) and speciﬁcity
(99.15%) reached the highest points (Figure 2A).
ROC analysis of serum miR-144 showed an AUC of 0.997 (95% CI
0.993–1.000, p < 0.001). When the cut-off value was 0.848, both
the sensitivity (99.19%) and speciﬁcity (94.87%) reached the
highest points (Figure 2B).
3.3. Expression of sputum and serum miR-144 in TB patients before
and after treatment
After treatment, sputum and serum miR-144 levels in the TB
patients decreased signiﬁcantly when compared to those
obtained before treatment (sputum 1.33  0.80 vs. 1.85  0.71,
t = 9.018; serum 0.99  0.67 vs. 1.31  0.30, t = 9.258; both
p < 0.05). Moreover, compared with the control group, the sputum
and serum miR-144 levels in the TB patients after treatment were
still signiﬁcantly higher (sputum 1.33  0.80 vs. 1.02  0.08,
t = 6.809; serum 0.99  0.60 vs. 0.72  0.08, t = 9.674; both
p < 0.001). The sputum and serum miR-144 levels were signiﬁcantly
lower in group A and group B after treatment than those before
treatment (all p < 0.05), while the changes were not signiﬁcant in
group C (p > 0.05). After treatment, the sputum miR-144 levels were
still signiﬁcantly higher in group A and group B patients than those in
group C patients and the control group (all p < 0.05), while no
signiﬁcant difference was found between group C patients and the
control group (p > 0.05). However, the serum miR-144 levels were
still signiﬁcantly higher in groups A, B, and C than those in the control
group (all p < 0.05) (Table 1).
3.4. Sputum and serum miR-144 expression levels before and after
treatment in patients with different treatment effects
The expression levels of sputum and serum miR-144 in the
improved TB patients were signiﬁcantly lower after treatment than
those before treatment (sputum 1.14  0.38 vs. 1.78  0.66,
t = 10.33; serum 0.87  0.22 vs. 1.29  0.30, t = 11.39; both and TB patients before treatment. Note: miR-144, microRNA-144; TB, tuberculosis.
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Figure 2. Diagnostic values of sputum (A) and serum (B) miR-144 for TB. Note: miR-144, microRNA-144; TB, tuberculosis.
Table 1
Expression of sputum and serum miR-144 in TB patients before and after treatmenta
Sputum Serum
Pre-treatment Post-treatment t p-Value Pre-treatment Post-treatment t p-Value
Healthy control group (n = 117) 1.02  0.08 0.72  0.08
Group A (n = 53) 2.49  0.48b 1.52  0.50b 13.178 <0.001 1.59  0.15b 1.02  0.30b 13.201 <0.001
Group B (n = 20) 1.80  0.09b,c 1.41  0.37b 4.436 <0.001 1.31  0.03b,c 1.03  0.21b 5.834 0.001
Group C (n = 51) 1.20  0.35b,c,d 1.10  0.45c,d 1.427 0.160 1.02  0.18b,c,d 0.94  0.33b 1.637 0.108
F 351.832 31.631 638.623 31.122
p-Value <0.001 <0.001 <0.001 0.363
miR-144, microRNA-144; TB, tuberculosis.
a Group A comprised TB patients with sputum positive for bacteria and pulmonary cavities; group B comprised TB patients with sputum negative for bacteria and
pulmonary cavities; group C comprised patients with sputum negative for bacteria and no pulmonary cavities.
b p < 0.05 compared with the healthy control group.
c p < 0.05 compared with group A.
d p < 0.05 compared with group B.
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in the non-improved TB patients had not changed signiﬁcantly after
treatment compared to those before treatment (sputum 1.95 
0.32 vs. 2.08  0.84, t = 1.115, p = 0.274; serum 1.37  0.21 vs.
1.38  0.30, t = 0.138; p = 0.891) (Figure 3). There were signiﬁcant
differences in sputum and serum miR-144 expression levels between
the control group and both the improved patients and the non-
improved patients after treatment (all p < 0.05). The sputum and
serum miR-144 levels decreased signiﬁcantly in the improved
patients in groups A, B, and C and also decreased signiﬁcantly in
the non-improved patients in group A after treatment compared to
those before treatment (all p < 0.001). The sputum and serum
expression levels of miR-144 were upregulated signiﬁcantly in the
non-improved patients in group C after treatment compared to those
before treatment (both p < 0.05). However, there was no signiﬁcant
difference in sputum or serum miR-144 levels in the non-improved
patients in group B before and after treatment (both p > 0.05)
(Tables 2 and 3).
4. Discussion
This study showed that the expression levels of sputum and
serum miR-144 in the TB patients were signiﬁcantly higher than
those in the control group before anti-TB treatment. The sputum
and serum miR-144 levels before treatment were signiﬁcantly
lower in the TB patients with sputum negative for bacteria andpulmonary cavities (group B) and TB patients with sputum
negative for bacteria and no cavities (group C) than those in the
TB patients with sputum positive for bacteria and cavities (group
A); the levels were also signiﬁcantly lower in group C than in group
B. These results indicate that sputum and serum miR-144 could be
used as diagnostic indices for TB and even for TB severity. This
suggestion is further rationalized by the ROC results, which
showed both sputum and serum miR-144 to have relatively high
sensitivity and speciﬁcity for the diagnosis of TB.
Macrophage cells, which are important in the early stage of
TB, can produce speciﬁc miRNA reactions in the process of TB
infection, and the miRNA can be detected in the blood of TB
patients.21 It has been found that the differential expression of
miRNA participates in the related signaling pathway of TB infection
by controlling the related signaling pathway.22 miRNA expression
proﬁling can provide useful information regarding the pathophys-
iology of active TB and could be used in determining the diagnosis
and prognosis of TB.23 The changes in sputum and serum levels of
miRNAs have great potential for use as non-invasive biomarkers
for the early detection of TB infection.24,25
Wang et al. also found the expression of miR-144 to be
upregulated in active TB patients compared with healthy controls,
suggesting that miR-144 may play a part in TB infection.26 Liu et al.
showed that miR-144* could prevent the production of two major
anti-TB immune factors, interferon gamma (IFN-g) and tumor
necrosis factor alpha (TNF-a), and could regulate the proliferation
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Figure 3. Sputum and serum expression levels of miR-144 in the healthy controls and TB patients with different treatment effects, before and after anti-TB treatment. Note:
miR-144, microRNA-144; TB, tuberculosis. Sputum (A) and serum (B) expression levels of miR-144 in the healthy control group and in the TB patients with improvement,
before and after anti-TB treatment. Sputum (C) and serum (D) expression levels of miR-144 in the healthy control group and in the TB patients with no improvement, before
and after anti-TB treatment. ***p < 0.001 compared with the healthy control group; ###p < 0.001 compared with before anti-TB treatment.
Table 2
Expression of sputum miR-144 before and after treatment in TB patients with different treatment effectsa
Sputum miR-144 expression
Improvement No improvement
n Pre-treatment Post-treatment t p-Value n Pre-treatment Post-treatment t p-Value
Healthy control group 1.02  0.08 1.02  0.08
Group A 40 2.37  0.39b 1.31  0.34b 12.371 <0.001 13 2.86  0.55b 2.18  0.27b 6.026 <0.001
Group B 16 1.82  0.08b,c 1.27  0.27b 7.368 <0.001 4 1.76  0.08b,c 1.93  0.21b,c 1.934 0.149
Group C 39 1.16  0.37b,c,d 0.91  0.33b,c,d 3.338 0.002 12 1.33  0.28b,c,d 1.71  0.19b,c,d 4.071 0.002
F 346.323 28.095 369.763 469.808
p-Value <0.001 <0.001 <0.001 <0.001
miR-144, microRNA-144; TB, tuberculosis.
a Group A comprised TB patients with sputum positive for bacteria and pulmonary cavities; group B comprised TB patients with sputum negative for bacteria and
pulmonary cavities; group C comprised patients with sputum negative for bacteria and no pulmonary cavities.
b p < 0.05 compared with the healthy control group.
c p < 0.05 compared with group A.
d p < 0.05 compared with group B.
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inhibit the expression of autophagy-related gene Atg4a and to
participate in the regulation of the autophagy process in
M. tuberculosis infection.27
Another important ﬁnding of the present study was that after
treatment, sputum and serum miR-144 levels in the TB patients
had decreased signiﬁcantly compared to those before treatment.
The sputum and serum levels of miR-144 were signiﬁcantly
lower in group A and group B patients after treatment than
those before treatment. All of the results indicate that the
expression levels of sputum and serum miR-144 may be used as
indices for the evaluation of the treatment effect. In a study onM. tuberculosis-positive patients, miR-30A was found to be
negatively correlated with beclin 1 and was found to decrease
after anti-TB treatment, indicating that miR-30A could play a key
role in the immune response against M. tuberculosis and serve as a
potential target for future TB treatments.28 Moreover, the serum
miR-155 level has been found to be negatively associated with the
TB-suppressing activity of natural killer cells and has also been
suggested as a potential therapeutic target for TB treatment.29
Maertzdorf et al. showed that miR-144, as a primary regulator of
the cell oxidative stress reaction, played an essential role in TB
therapy, which was reﬂected in the regulation of T-cell products
in the course of the T-cell immune response.30
Table 3
Expression of serum miR-144 before and after treatment in TB patients with different treatment effectsa
Serum miR-144 expression
Improvement No improvement
n Pretreatment Post-treatment t p-Value n Pretreatment Post-treatment t p-Value
Healthy control group 0.72  0.08 0.72  0.08
Group A 40 1.56  0.13b 0.89  0.17b 16.604 <0.001 13 1.65  0.19b 1.40  0.27b 3.495 0.004
Group B 16 1.31  0.03b,c 0.95  0.03b 8.311 <0.001 4 1.30  0.05b,c 1.31  0.03b 0.714 0.527
Group C 39 1.00  0.20b,c,d 0.81  0.29b,c,d 3.428 0.001 12 1.11  0.11b,c,d 1.34  0.16b 4.635 0.001
F 564.149 21.18 435.28 243.009
p-Value <0.001 <0.001 <0.001 <0.001
miR-144, microRNA-144; TB, tuberculosis.
a Group A comprised TB patients with sputum positive for bacteria and pulmonary cavities; group B comprised TB patients with sputum negative for bacteria and
pulmonary cavities; group C comprised patients with sputum negative for bacteria and no pulmonary cavities.
b p < 0.05 compared with the healthy control group.
c p < 0.05 compared with group A.
d p < 0.05 compared with group B.
Y. Lv et al. / International Journal of Infectious Diseases 43 (2016) 68–73 73In conclusion, in this study it was found that sputum and serum
miR-144 levels in TB patients were upregulated signiﬁcantly, but
that they decreased signiﬁcantly after anti-TB treatment, suggest-
ing the potential application of sputum and serum miR-144 levels
in the diagnosis of TB and in evaluating the effects of TB treatment.
Further studies should focus on identifying the underlying
mechanisms of miR-144 in the development of TB.
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